Biocompounding
3 Top Biotech News Of The Week (22 Oct 2022) - Oculis, LLY, AKUS, JAZZ, ZYME
1) Another ophthalmology acquisition: Oculis. SA and European Biotech Acquisition Corp. announce business combination agreement
The resultant company, Oculis Holding SA will work to accelerate the development of Oculis’s differentiated ophthalmology pipeline therapeutics for diabetic macular edema, dry eye disease, and neuro-retina indications such as glaucoma.
Oculis’ pipeline
A look at Nimbus & Eli Lilly's AMPK Collaboration, Regeneron and Sanofi's Dupixent EOE approval and Merck's Sotatercept for PAH
1) Eli Lilly (NYSE: LLY) enters into collaboration with Nimbus to develop therapeutics for metabolic diseases
Eli Lilly and Nimbus enter into a collaboration to develop therapeutics for metabolic diseases.
The two companies will collaborate on the development of novel targeted therapies designed to activate a specific isoform of AMPK
3 Top Biotech News Of The Week (8 October 22) - BMS, AUTL, DNA, Svante Pääbo discovery
1) Bristol Myers Squibb (BMS) enters into 2 licensing deals with SynethX and Autolus Therapeutics (AUTL)
Bristol Myers Squibb (NYSE: BMS) entered into 2 licensing deals with SynethX Inc and Autolus Therapeutics (NASDAQ: AUTL).
The first deal is with SynethX which will focus on discovering molecular glue degraders. Synethx has
A Biotech Growth Stock to Consider For Your Portfolio - Sarepta Therapeutics (NASDAQ: SRPT)
3 Top Biotech News Of The Week (1 October 22)
1) Eisai and Biogen Report Positive Phase III Data for Anti-Amyloid Alzheimer's Drug
Eisai and Biogen announced that the duo’s Alzheimer's drug, Lecanemab, slowed the rate of cognitive decline for early Alzheimer’s participants in the phase 3 clinical trial by 27% compared to
An Overview of RNA Technologies
RNA technologies made headlines in 2021 when the first mRNA-based COVID-19 vaccine was approved in December 2020.
However, RNA therapy is not a new technology. RNA modalities have been under development for several decades and by Jan 2020, the U.S Food and Drug Administration (FDA) had approved